je.st
news
Home
› Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin
Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin
2013-06-05 01:19:14| Logistics - Topix.net
Aeterna Zentaris Inc. today announced that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin , demonstrated the compound's promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer.
Tags: with
data
final
trial
Category:Transportation and Logistics
Latest from this category |
All news |
||||||||||||||||||
|
|||||||||||||||||||